Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, Taipei Medical University, Shuang Ho Hospital, New Taipei City, Taiwan.
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
J Microbiol Immunol Infect. 2024 Jun;57(3):365-374. doi: 10.1016/j.jmii.2024.02.005. Epub 2024 Mar 6.
Cytomegalovirus (CMV) can cause infection and critical diseases in hematopoietic stem cell transplantation (HSCT) recipients. This study aimed to explore the cumulative incidence and risk factors for CMV infection and disease among HSCT recipients in Taiwan.
This retrospective cohort study using the Taiwan Blood and Marrow Transplantation Registry (TBMTR) included HSCT recipients between 2009 and 2018 in Taiwan. The primary outcome was cumulative incidence of CMV infection or disease at day 100 after HSCT. Secondary outcomes included day 180 cumulative incidence of CMV infection or disease, infection sites, risk factors for CMV infection or disease, survival analysis, and overall survival after CMV infection and disease.
There were 4394 HSCT recipients included in the study (2044 auto-HSCT and 2350 allo-HSCT). The cumulative incidence of CMV infection and disease was significantly higher in allo-HSCT than in auto-HSCT patients at day 100 (53.7% vs. 6.0%, P < 0.0001 and 6.1% vs. 0.9%, P < 0.0001). Use of ATG (HR 1.819, p < 0.0001), recipient CMV serostatus positive (HR 2.631, p < 0.0001) and acute GVHD grades ≥ II (HR 1.563, p < 0.0001) were risk factors for CMV infection, while matched donor (HR 0.856, p = 0.0180) and myeloablative conditioning (MAC) (HR 0.674, p < 0.0001) were protective factors.
The study revealed a significant disparity in terms of the incidence, risk factors, and clinical outcomes of CMV infection and disease between auto and allo-HSCT patients. These findings underscore the importance of considering these factors in the management of HSCT recipients to improve outcomes related to CMV infections.
巨细胞病毒(CMV)可导致造血干细胞移植(HSCT)受者感染和发生重症疾病。本研究旨在探索台湾地区 HSCT 受者 CMV 感染和疾病的累积发生率和危险因素。
本回顾性队列研究使用了台湾血液和骨髓移植登记处(TBMTR)的数据,纳入了 2009 年至 2018 年间在台湾接受 HSCT 的患者。主要结局是 HSCT 后 100 天 CMV 感染或疾病的累积发生率。次要结局包括 HSCT 后 180 天 CMV 感染或疾病的累积发生率、感染部位、CMV 感染或疾病的危险因素、生存分析以及 CMV 感染和疾病后的总生存率。
本研究纳入了 4394 例 HSCT 受者(2044 例自体 HSCT 和 2350 例异体 HSCT)。异体 HSCT 患者 100 天的 CMV 感染和疾病累积发生率明显高于自体 HSCT 患者(53.7% vs. 6.0%,P<0.0001;6.1% vs. 0.9%,P<0.0001)。使用 ATG(HR 1.819,p<0.0001)、受者 CMV 血清学阳性(HR 2.631,p<0.0001)和急性移植物抗宿主病(GVHD)分级≥Ⅱ级(HR 1.563,p<0.0001)是 CMV 感染的危险因素,而匹配供者(HR 0.856,p=0.0180)和清髓性预处理(MAC)(HR 0.674,p<0.0001)是保护性因素。
本研究揭示了自体和异体 HSCT 患者之间 CMV 感染和疾病的发生率、危险因素和临床结局存在显著差异。这些发现强调了在 HSCT 受者管理中考虑这些因素的重要性,以改善与 CMV 感染相关的结局。